An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease
Douglas K. Brubaker, Manu P. Kumar, Evan L. Chiswick, Cecil Gregg, Alina Starchenko, Paige N. Vega, Austin N. Southard-Smith, Alan J. Simmons, Elizabeth Scoville, Lori A. Coburn, Keith T. Wilson, Ken S. Lau, Douglas A. Lauffenburger
Abstract
integrin subunit mediated the effectiveness of anti-TNF therapy in human immune cells. Thus, TransComp-R identified an integrin signaling mechanism with potential therapeutic implications for overcoming anti-TNF therapy resistance. We suggest that TransComp-R is a generalizable framework for addressing species, molecular, and phenotypic discrepancies between model systems and patients to translationally deliver relevant biological insights.
Topics & Concepts
Inflammatory bowel diseaseInfliximabIntegrinTranslation (biology)Signal transductionMedicineCancer researchDiseaseCell biologyBiologyImmunologyTumor necrosis factor alphaGeneticsPathologyCellGeneMessenger RNAInflammatory Bowel DiseaseMycobacterium research and diagnosisImmunodeficiency and Autoimmune Disorders